| Cat. No. |
Product Name |
Information |
| PC-38887 |
Zansecimab
Anti-ANGPT2 mAb
|
Zansecimab (LY3127804) is a humanized IgG4 monoclonal antibody that targets angiopoietin 2 (Ang2), neutralizes phospho-Tie2 induction due to Ang2, thereby stopping angiogenesis. |
| PC-38886 |
Olokizumab
Anti-IL-6 mAb
|
Olokizumab is a humanized antibody targeting interleukin-6 (IL-6), binds to IL-6 at Site 3 and neutralizes biological activity through blocking hexamer formation on the gp130 signaling axis. |
| PC-38885 |
Tamtuvetmab
Anti-Canine CD52 mAb
|
Tamtuvetmab is a recombinantchimeric (dog/rat) monoclonal antibody against CD52, with potential in the treatment of veterinary antineoplastic. |
| PC-38884 |
Blontuvetmab
Anti-MS4A1 (CD20) mAb
|
Blontuvetmab is a caninized monoclonal antibody that targets MS4A1/CD20, can be potentially used in the treatment of Canine B-cell lymphoma. |
| PC-Ab1061 |
Urabrelimab
|
SRF-231 is fully human mAb for CD47, binds with high affinity to CD47, stimulates phagocytosis and the killing of cancer cells in vitro and has potent anti-tumor activity preclinically, both as monotherapy and in combination settings.disrupts the CD47/SIRPα interaction without causing hemagglutination or RBC phagocytosis. SRF231 exerts antitumor activity in vitro through both phagocytosis and cell death in a manner dependent on the activating Fc-gamma receptor (FcγR), CD32a. In tumor-bearing mic |
| PC-24499 |
Tozorakimab
Anti-IL-33 mAb
|
Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33 (IL-33), blocks IL-33red and IL-33ox signalling, reduces inflammation and epithelial dysfunction. |
| PC-23699 |
Visugromab
Anti-GDF-15 mAb
|
Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb, shows synergistic anticancer activity with the anti-PD1 antibody Nivolumaband can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. |
| PC-22987 |
Infliximab
Anti-TNF-α mAb
|
Infliximab (Avakine, CT-P13) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α, prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). |
| PC-49138 |
Denecimig
Anti-Factor IX
|
Delpacibart is a humanized, bispecific, bivalent monoclonal antibody against F9 (coagulation factor
9, coagulation factor IX). Isotype: IgG4-kappa. Anti-[F9 (coagulation factor 9, coagulation factor IX) activated form and F10 (coagulation factor 10, coagulation factor X)], human monoclonal antibody, bispecific, bivalent. |
| PC-49137 |
Delpacibart
Anti-TFRC
|
Delpacibart is a humanized mnonoclonal antibody against TFRC transferrin receptor (TfR1). Isotype: IgG1-kappa. Anti-[human TFRC (transferrin receptor, TfR1)], humanized monoclonal antibody. |
| PC-49136 |
Dargistotug
Anti-TIGIT
|
Dargistotug is a humanized mnonoclonal antibody against TIGIT (VSIG9). Isotype: IgG1-kappa. Anti-[human TIGIT (T-cell immunoreceptor with Ig domain and ITIM, V-set Ig member 9, VSIG9, V-set and transmembrane member 3, VSTM3)], human monoclonal antibody. |
| PC-49135 |
Danvilostomig
Anti-CTLA4/PD-1
|
IgG1-kappa_scFv, anti-[human CTLA4 (cytotoxic T-lymphocyte-associated antigen 4, cytotoxic Tlymphocyte-associated protein 4, CTLA-4, CD152)], each heavy chain being fused to a scFv anti-human PDCD1 (programmed cell death 1, PD1, PD-1, CD279)], human and humanized monoclonal antibody, tetravalent, bispecific. |
